Also trades as: 0IGA.L (LSE) · $vol 0M
EBS NYSE
Emergent BioSolutions Inc.
1W: +6.0%
1M: -2.8%
3M: -9.2%
YTD: -46.7%
1Y: -31.5%
3Y: +201.8%
5Y: -86.9%
$6.67
+0.33 (+5.21%)
Weekly Expected Move ±10.7%
$5
$6
$6
$7
$8
Credit Risk of going bust: higher than 91% of companies Debt: 63.0% of company value Bonds: $63.5M held by 75 funds, 397 bp over Treasuries → details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.14 (down 83%), Emergent BioSolutions Inc. would be worth roughly what it owes.
Total debt $581.8M against a stock market value of $342.0M.
Distance to default 1.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $290.9M (short-term plus half of long-term), stock volatility 81.1%; Altman Z 0.84. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.14 (down 83%), Emergent BioSolutions Inc. would be worth roughly what it owes.
Total debt $581.8M against a stock market value of $342.0M.
Distance to default 1.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $290.9M (short-term plus half of long-term), stock volatility 81.1%; Altman Z 0.84. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships10
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2022-09-26
Earliest Filing
2024-07-31
Latest Filing
acquirer: 4
customer: 3
partner: 2
target: 1
Counterparties (Filed by EBS)
10 relationshipsCompanies named in EBS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| SERB Pharmaceuticals | — | acquirer | Acquired worldwide rights to RSDL, EPPU, and related assets from Emergent BioSolutions Inc. | 2024-07-31 | View |
| BTG International Inc. | — | acquirer | Wholly owned subsidiary of SERB Pharmaceuticals that entered into the Stock and Asset Purchase Agreement. | 2024-07-31 | View |
| U.S. Department of Health and Human Services | — | customer | Federal agency overseeing the ASPR contract for ACAM2000 vaccine supply. | 2024-07-02 | View |
| Biomedical Advanced Research and Development Authority | — | customer | BARDA agency that awarded the AV7909 contract modification for CYFENDUS. | 2024-07-02 | View |
| Evercore Group L.L.C. | EVR | partner | Sales agent for the at-the-market equity offering | 2023-05-18 | View |
| RBC Capital Markets, LLC | — | partner | Sales agent for the at-the-market equity offering | 2023-05-18 | View |
| Bavarian Nordic | — | customer | Purchased the registrant's travel health business | 2023-05-18 | View |
| Bavarian Nordic | — | acquirer | Acquired Emergent BioSolutions Inc.'s travel health business including Vivotif, Vaxchora, and manufacturing sites for $2 | 2023-05-15 | View |
| Bavarian Nordic | — | acquirer | Acquired Emergent BioSolutions' travel health business including Vivotif, Vaxchora, and manufacturing sites for $270 mil | 2023-02-15 | View |
| Chimerix, Inc. | — | target | Seller of exclusive worldwide rights to brincidofovir, including TEMBEXA, acquired by Emergent BioSolutions Inc. | 2022-09-26 | View |
Mentioned As Counterparty
1 mentionsOther companies that named EBS in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-16 | Officer/Director Change; Exhibits | View | |
| 2026-09-14 | Regulation FD; Exhibits | View | |
| 2026-09-01 | Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exit/Disposal Costs; Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-29 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-04-30 | Shareholder Vote; Exhibits | View | |
| 2026-04-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-17 | Material Agreement; Termination of Agreement; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-03-03 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-12 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-29 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-09-11 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-09-05 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR